What is claimed:

1. Use of a pharmaceutical composition comprising immune stimulators in the manufacture of a medicament for treating cancer or a metastasis thereof in a subject, wherein the pharmaceutical composition comprises an alpha thymosin peptide and a programmed cell death-1 (PD-1) inhibitor.

2. The use of claim 1, wherein the subject is a human.

3. The use of claim 1, wherein the composition further comprises an additional anti-melanoma agent.

4. The use of claim 1, wherein the alpha thymosin peptide is to be administered to the subject during at least a portion of the treatment at a dosage within a range of about 0.5-10 mg/day.

5. The use of claim 1, wherein the alpha thymosin peptide is thymosin alpha 1 (TA1).

6. The use of claim 5, wherein the TA1 is to be administered daily for a period of about 1-10 days, followed by about 1-5 days of non-administration of TA1.

7. The use of claim 6, wherein TA1 is to be administered daily for about 3-5 days, followed by about 2-4 days of non-administration of TA1.

8. The use of claim 7, wherein TA1 is to be administered daily for about 4 days, followed by about 3 days non-administration of TA1.

9. The use of claim 1, wherein the composition further comprises a kinase inhibitor, an antineoplastic heat shock apoptosis activator (HSAA), an antibody against cytotoxic T lymphocyte-associated antigen 4 (CTLA4), an alkylating antineoplastic agent (AlkAA), or a chemotherapeutic agent.

10. The use of claim 1, wherein the cancer is melanoma.